Catalyst Capital Advisors’s Trevi Therapeutics TRVI Stock Holding History

Catalyst Capital Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-850	Closed	-$6K	–	480
2019 Q2	$6K	Buy	+850	New	+$7.32K	﹤0.01%	380

Other funds holding TRVI

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalyst Capital Advisors's TRVI Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of Trevi Therapeutics (TRVI) in Q3 2019, closing a stake of 850 shares — an estimated $6K sold.

Catalyst Capital Advisors first reported a position in TRVI in Q2 2019 and held it in 1 quarter. The position peaked at $6K in Q2 2019. 20 funds tracked by Wall St. Rank hold TRVI as of Q3 2019.

Catalyst Capital Advisors reported no remaining Trevi Therapeutics position as of Q3 2019 after selling out during the quarter.
Catalyst Capital Advisors sold 850 Trevi Therapeutics shares in Q3 2019, an estimated $6K.
Catalyst Capital Advisors first reported a position in Trevi Therapeutics in Q2 2019 and held it in 1 quarter.
Catalyst Capital Advisors's Trevi Therapeutics position peaked at $6K in Q2 2019.
20 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.